- Home
- NMTC
as 07-26-2024 4:00pm EST
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | EDEN PRAIRIE |
| Market Cap: | 23.9M | IPO Year: | N/A |
| Target Price: | $2.20 | AVG Volume (30 days): | 61.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.65 - $2.00 | Next Earning Date: | 08-12-2024 |
| Revenue: | $3,726,629 | Revenue Growth: | -8.64% |
| Revenue Growth (this year): | 109.53% | Revenue Growth (next year): | 90.00% |
Stock Insider Trading Activity of NeuroOne Medical Technologies Corporation (NMTC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Christianson Mark | NMTC | Business Development Director | Jun 6 '24 | Sell | $0.88 | 2,189 | $1,917.56 | 295,035 | SEC Form 4 |
| Christianson Mark | NMTC | Business Development Director | Jun 5 '24 | Sell | $0.88 | 25,800 | $22,662.72 | 297,224 | SEC Form 4 |
| Christianson Mark | NMTC | Business Development Director | Dec 26 '23 | Sell | $1.35 | 6,848 | $9,269.45 | 332,039 | SEC Form 4 |
| Christianson Mark | NMTC | Business Development Director | Dec 26 '23 | Sell | $1.46 | 31,445 | $45,859.39 | 300,594 | SEC Form 4 |
| Christianson Mark | NMTC | Business Development Director | Dec 21 '23 | Sell | $1.40 | 9,907 | $13,869.80 | 340,687 | SEC Form 4 |
| Christianson Mark | NMTC | Business Development Director | Dec 21 '23 | Sell | $1.40 | 1,800 | $2,520.00 | 338,887 | SEC Form 4 |
| Volker Christopher | NMTC | Chief Operating Officer | Dec 21 '23 | Buy | $1.40 | 75,000 | $105,000.00 | 75,000 | SEC Form 4 |
Latest NeuroOne Medical Technologies Corporation News
NMTC Breaking Stock News: Dive into NMTC Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
NeuroOne® Announces First in Human Ablations Completed with OneRF™ Ablation System
GlobeNewswire
a month ago
NeuroOne® Granted Approval of ICD-10 Procedure Code for sEEG RF Ablation
GlobeNewswire
2 months ago
NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
3 months ago
NeuroOne® to Report Second Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on May 14
Simply Wall St.
3 months ago
Favourable Signals For NeuroOne Medical Technologies: Numerous Insiders Acquired Stock
GlobeNewswire
4 months ago
NeuroOne® CEO Dave Rosa Featured on Bloomberg Technology
GlobeNewswire
4 months ago
NeuroOne® Announces First Implant of OneRF™ Ablation Electrodes
GlobeNewswire
4 months ago
NeuroOne® CEO Dave Rosa Featured on Fox Business Network’s Varney & Co.
Compare NMTC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NMTC NeuroOne Medical Technologies Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.